Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16674
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorrow, Riley J-
dc.contributor.authorEtemadi, Nima-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorErnst, Matthias-
dc.date2017-05-21-
dc.date.accessioned2017-06-15T07:33:24Z-
dc.date.available2017-06-15T07:33:24Z-
dc.date.issued2017-05-21-
dc.identifier.citationMediators of Inflammation 2017; 2017: 4754827en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16674-
dc.description.abstractInflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations. The clinical presentation of inflammatory breast cancer often differs significantly from that of noninflammatory breast cancer; however, immunohistochemistry reveals few, if any, distinguishing features. The more aggressive triple-negative and HER2-positive breast cancer subtypes are overrepresented in inflammatory breast cancer compared with noninflammatory breast cancer, with a poorer prognosis in response to conventional therapies. Despite its name, there remains some controversy regarding the role of inflammation in inflammatory breast cancer. This review summarises the current molecular evidence suggesting that inflammatory signaling pathways are upregulated in this disease, including NF-κB activation and excessive IL-6 production among others, which may provide an avenue for novel therapeutics. The role of the tumor microenvironment, through tumor-associated macrophages, infiltrating lymphocytes, and cancer stem cells is also discussed, suggesting that these tumor extrinsic factors may help account for the differences in behavior between inflammatory breast cancer and noninflammatory breast cancer. While there are various novel treatment strategies already underway in clinical trials, the need for further development of preclinical models of this rare but aggressive disease is paramount.en_US
dc.titleChallenging a misnomer? The role of inflammatory pathways in inflammatory breast canceren_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMediators of Inflammationen_US
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28607534en_US
dc.identifier.doi10.1155/2017/4754827en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-2283-3970-
dc.identifier.orcid0000-0002-9218-9917-
dc.type.austinJournal Articleen_US
local.name.researcherErnst, Matthias
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Dec 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.